Thorsten Waloschek/LinkedIn
Dec 21, 2025, 02:24
Thorsten Waloschek: New Study Highlights Preeclampsia Risk Stratification Benefits
Thorsten Waloschek, CEO of NeoPredics AG, shared a post on LinkedIn:
“This is an important signal for maternal health innovation in pregnancy.
A large new study shows that identifying women at higher risk of preeclampsia late in pregnancy, and acting on that risk with planned early-term birth, reduced term preeclampsia by around 30%.
Risk stratification, biomarkers, and structured decision-making during pregnancy can change outcomes – even without new drugs. This reinforces how much potential still sits in smarter diagnostics and data-driven pathways to protect mothers’ cardiovascular health during pregnancy.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jun 19, 2026, 15:54Horace Roman: Sciatic Nerve Endometriosis – Prevent Muscle Atrophy Caused by Progressive Denervation
-
Jun 19, 2026, 15:36Why Does the Clock Read Older? – Fertility Plus
-
Jun 19, 2026, 15:28Asma Khalil: Study Raises Questions About Workplace Activities and Early Pregnancy Outcomes
-
Jun 19, 2026, 15:21Spindle Dynamics and Chromosome Segregation In Human Preimplantation Embryos – Fertility and Sterility
-
Jun 19, 2026, 15:12Today is World Sickle Cell Day – Preeclampsia Foundation
-
Jun 19, 2026, 14:59Marco Zaccaria: ESGE Webinar to Spotlight Advances in the Surgical Management of Parametrial Endometriosis
-
Jun 19, 2026, 14:46PMOS Does Not Make Conception Impossible – PCOS Awareness Association
-
Jun 19, 2026, 14:40Diana Kayal: Successful Fertility Programs Aren’t Built On Clinical Expertise Alone
-
Jun 19, 2026, 14:29Devyanshi Dixit: Call for Abstracts at GFWH 2026